Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Wei

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|July 21, 2012
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapseChun Yew Fong, George Grigoriadis, Jay Hocking, et al.
Oncotarget|September 9, 2017
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II studyPeter Tan, Ing Soo Tiong, Shaun Fleming, et al.
Asia-Pacific Journal of Clinical Oncology|June 1, 2023
Asia-Pacific Leukemia Consortium: An innovative and collaborative initiative to improve care of leukemia and related diseases in the Asia-Pacific regionZhentang Lao, Eric Wai Choi Tse, Suporn Chuncharunee, et al.
Journal of Pediatric Surgery|October 28, 2018
Nebulized analgesia during laparoscopic appendectomy (NALA): A randomized triple-blind placebo controlled trialRobert Baird, Pablo Ingelmo, Andrew Wei, et al.
Molecular Cell|February 8, 2005
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic functionLin Chen, Simon N Willis, Andrew Wei, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
Transfusion|July 16, 2015
Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantationTina Pham, Sushrut Patil, Shaun Fleming, et al.
JCO Precision Oncology|October 5, 2020
Systematic Assessment of Tumor Purity and Its Clinical ImplicationsSyed Haider, Svitlana Tyekucheva, Davide Prandi, et al.
Cancer|April 23, 2013
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemiaHagop M Kantarjian, Giovanni Martinelli, Elias J Jabbour, et al.
Internal Medicine Journal|May 23, 2025
Frailty and geriatric assessments in older patients diagnosed with acute myeloid leukaemia: an Australasian Leukaemia and Lymphoma Group consensus statementBriony Shaw, Victoria Yee-May Ling, Ruth E Hubbard, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|July 21, 2012
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapseChun Yew Fong, George Grigoriadis, Jay Hocking, et al.
Oncotarget|September 9, 2017
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II studyPeter Tan, Ing Soo Tiong, Shaun Fleming, et al.
Asia-Pacific Journal of Clinical Oncology|June 1, 2023
Asia-Pacific Leukemia Consortium: An innovative and collaborative initiative to improve care of leukemia and related diseases in the Asia-Pacific regionZhentang Lao, Eric Wai Choi Tse, Suporn Chuncharunee, et al.
Journal of Pediatric Surgery|October 28, 2018
Nebulized analgesia during laparoscopic appendectomy (NALA): A randomized triple-blind placebo controlled trialRobert Baird, Pablo Ingelmo, Andrew Wei, et al.
Molecular Cell|February 8, 2005
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic functionLin Chen, Simon N Willis, Andrew Wei, et al.
British Journal of Haematology|December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasmStéphane De Botton, Christian Récher, Jorge Cortes, et al.
Transfusion|July 16, 2015
Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantationTina Pham, Sushrut Patil, Shaun Fleming, et al.
JCO Precision Oncology|October 5, 2020
Systematic Assessment of Tumor Purity and Its Clinical ImplicationsSyed Haider, Svitlana Tyekucheva, Davide Prandi, et al.
Cancer|April 23, 2013
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemiaHagop M Kantarjian, Giovanni Martinelli, Elias J Jabbour, et al.
Internal Medicine Journal|May 23, 2025
Frailty and geriatric assessments in older patients diagnosed with acute myeloid leukaemia: an Australasian Leukaemia and Lymphoma Group consensus statementBriony Shaw, Victoria Yee-May Ling, Ruth E Hubbard, et al.
Pageof 10